Medical device co Otomedics signs with US distributor

Jedmed will distribute the company's innovative device for treating ear infections.

Otomedics has signed a distribution agreement in the US, after obtaining US Food and Drug Administration (FDA) approval.

Otomedics has signed an agreement with Jedmed Instrument Co., which will be the North America distributor for the implant developed by Otomedics for treating ear infections. The implant goes by the interesting name of U-Tube. Otomedics also expects to receive CE approval for selling the product in Europe.

The company is a graduate of the Mofet B''Yehuda Technological Incubator. Its product has a shape and properties different from those of existing products, and it is meant to provide a general solution to a variety of ear infections.

The implant was developed under a patent of Dr. David Cohen, formerly head of the Ear Nose and Throat Department at Shaare Zedek Hospital in Jerusalem. The company says that it gives the physician complete control during treatment.

"We are proud and happy at the confidence that Jedmed has placed in us, and at the prospect of cooperating with it," Otomedics CEO Yossi Shechter said today. According to Shechter, doctors in the US say they have waited for a product offering substantial innovation in this field for over twenty years.

Jedmed distributes medical equipment in various fields of medicine, mainly ear nose and throat, dentistry, and ophthalmology. The company exhibited Otomedics' implant at a professional convention in Las Vegas, and says the response was enthusiastic.

Published by Globes [online], Israel business news - www.globes-online.com - on May 12, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017